Ziccum CEO holds a Q&A session regarding current activities and dialogues

ZiccumPress release2024-11-27 09:00

Ziccum’s CEO, Ann Gidner, in Questions & Answers session moderated by analyst Jonathan Furelid.

Ann Gidner joins Jonathan Furelid in a Q&A session providing more background regarding on-going Ziccum activities and business dialogues. The questions, nicely curated by Ziccum shareholders, are addressing topics including technology and business development, scientific milestones, resource allocation, and soft funding opportunities.

You may access the recorded session here: https://youtu.be/OIdwath65Qc

About Ziccum

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.